$146 Million is the total value of First Light Asset Management, LLC's 62 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEO | Buy | NEOGENOMICS INCcs | $12,977,000 | +91.8% | 2,490,848 | +22.2% | 8.88% | +94.8% |
| IG | Buy | IGI INCcs | $11,412,000 | +79.9% | 1,224,503 | +2.5% | 7.81% | +82.7% |
| SPNC | Buy | SPECTRANETICS CORPcs | $7,762,000 | +19.0% | 292,124 | +2.5% | 5.31% | +20.9% |
| AKRXQ | Buy | AKORN INCcs | $7,744,000 | +11.8% | 213,512 | +2.5% | 5.30% | +13.5% |
| ATRC | Buy | ATRICURE INCcs | $7,311,000 | -17.9% | 496,671 | +2.6% | 5.00% | -16.6% |
| RTIX | Buy | RTI BIOLOGICS INCcs | $6,402,000 | +12.7% | 1,339,291 | +2.5% | 4.38% | +14.4% |
| ENZ | Buy | ENZO BIOCHEM INCcs | $5,853,000 | +0.5% | 1,136,575 | +2.4% | 4.00% | +2.0% |
| NXTM | Buy | NXSTAGE MEDICAL INCcs | $4,545,000 | +70.0% | 346,177 | +86.0% | 3.11% | +72.6% |
| HBIO | Buy | HARVARD BIOSCIENCE INCcs | $4,351,000 | -5.7% | 1,063,840 | +4.9% | 2.98% | -4.3% |
| STRM | Buy | STREAMLINE HEALTH SOLUTIONScs | $3,918,000 | -1.3% | 846,212 | +2.4% | 2.68% | +0.3% |
| ARRY | Buy | ARRAY BIOPHARMA INCcs | $3,782,000 | -19.6% | 1,059,270 | +2.6% | 2.59% | -18.4% |
| LGND | Buy | LIGAND PHARMACEUTICALS INCcs | $3,588,000 | -22.5% | 76,366 | +2.7% | 2.45% | -21.4% |
| QDEL | Buy | QUIDEL CORPcs | $3,571,000 | +24.7% | 132,885 | +2.6% | 2.44% | +26.6% |
| TECH | Buy | TECHNE CORPcs | $3,421,000 | +3.6% | 36,566 | +2.5% | 2.34% | +5.2% |
| SPPI | Buy | SPECTRUM PHARMACEUTICALS INCcs | $3,081,000 | +3.0% | 378,537 | +2.9% | 2.11% | +4.6% |
| TEAR | Buy | TEARLAB CORPcs | $3,048,000 | -28.4% | 896,464 | +2.6% | 2.08% | -27.3% |
| STAA | Buy | STAAR SURGICAL COcs | $3,027,000 | -12.0% | 284,730 | +39.2% | 2.07% | -10.6% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLCcs | $2,898,000 | -7.1% | 189,766 | +2.4% | 1.98% | -5.7% |
| ALKS | Buy | ALKERMES PLCcs | $2,805,000 | -12.5% | 65,423 | +2.7% | 1.92% | -11.1% |
| SNY | Buy | SANOFI-SYNTHELABOadr | $2,801,000 | +827.5% | 49,633 | +773.8% | 1.92% | +843.8% |
| NVDQ | Buy | NOVADAQ TECHNOLOGIES INCcs | $2,641,000 | -21.2% | 208,121 | +2.4% | 1.81% | -19.9% |
| ELGX | Buy | ENDOLOGIX INCcs | $2,455,000 | +73.9% | 231,599 | +149.4% | 1.68% | +76.6% |
| SGNT | Buy | SAGENT PHARMACEUTICALS INCcs | $2,194,000 | +23.6% | 70,542 | +2.8% | 1.50% | +25.5% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEWcs | $1,851,000 | -18.6% | 142,811 | +2.5% | 1.27% | -17.4% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INCcs | $1,829,000 | +21.9% | 16,285 | +2.8% | 1.25% | +23.7% |
| FLDM | Buy | FLUIDIGM CORP DELcs | $1,825,000 | -14.3% | 74,482 | +2.8% | 1.25% | -13.0% |
| HSTM | Buy | HEALTHSTREAM INCcs | $1,825,000 | +1.6% | 76,014 | +2.8% | 1.25% | +3.1% |
| CPHD | Buy | CEPHEIDcs | $1,817,000 | -5.6% | 41,272 | +2.8% | 1.24% | -4.1% |
| ALGN | Buy | ALIGN TECHNOLOGY INCcs | $1,754,000 | -5.2% | 33,934 | +2.7% | 1.20% | -3.8% |
| ABCO | Buy | ADVISORY BRD COcs | $1,688,000 | -7.7% | 36,226 | +2.8% | 1.16% | -6.2% |
| LMAT | Buy | LEMAITRE VASCULAR INCcs | $1,672,000 | -14.4% | 242,968 | +2.8% | 1.14% | -13.1% |
| STKL | Buy | SUNOPTA INCcs | $1,479,000 | -10.6% | 122,576 | +4.3% | 1.01% | -9.2% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INCcs | $1,467,000 | +19.4% | 20,325 | +2.9% | 1.00% | +21.3% |
| ISIS | New | ISIS PHARMACEUTICALS INCcs | $1,060,000 | – | 27,290 | +100.0% | 0.72% | – |
| ANGO | Buy | ANGIODYNAMICS INCcs | $958,000 | -13.5% | 69,822 | +3.0% | 0.66% | -12.2% |
| CYTK | Buy | CYTOKINETICS INC COMcs | $581,000 | -24.7% | 165,046 | +2.2% | 0.40% | -23.7% |
| PETX | Buy | ARATANA THERAPEUTICS INCcs | $539,000 | -33.9% | 53,667 | +2.7% | 0.37% | -32.8% |
| B108PS | New | ACTAVIS PLCcs | $491,000 | – | 2,035 | +100.0% | 0.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-06-10 |
| SC 13G/A | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.